


Data Sheet

Product Name:	AMY-101 (TFA)
Cat. No.:	CS-0119743
CAS No.:	1789738-04-0
Molecular Formula:	C ₈₃ H ₁₁₇ N ₂₃ O ₁₈ S ₂ .xC ₂ HF ₃ O ₂
Molecular Weight:	1789.09 (free base)
Target:	Complement System; SARS-CoV
Pathway:	Anti-infection; Immunology/Inflammation
Solubility:	H ₂ O : ≥ 50 mg/mL; DMSO : ≥ 50 mg/mL



BIOLOGICAL ACTIVITY:

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central **complement component C3** ($K_D = 0.5$ nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation^{[1][2]}. IC₅₀ & Target:KD: 0.5 nM (C3)^[1]. *In Vivo*: AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis^[1].

AMY-101 can induce a long-lasting anti-inflammatory effect^[1].

AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction^[1].

AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis^[3].

References:

[1]. Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. *Mol Ther Methods Clin Dev.* 2017 Aug 18;6:207-215.

[2]. Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. *Clin Immunol.* 2020 Apr 29;108450.

[3]. Yanyan Liu, et al. Complement C3 Produced by Macrophages Promotes Renal Fibrosis via IL-17A Secretion. *Front Immunol.* 2018 Oct 22;9:2385.

CAIndexNames:

L-Isoleucinamide, D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutamyl-L-α-aspartyl-L-tryptophyl-N-methylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N2-methyl-, cyclic (3→13)-disulfide (TFA)

SMILES:

OC(C(F)(F)F)=O.CN1C2=CC=CC=C2C([C@H]3C(N[C@H](C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N3)=O)C(C)=O)NC([C@H]([C@@H](C)CC)NC([C@H](N)CC4=CC=C(C=C4)O)=O)O)C(N(C)[C@H](C(N)=O)[C@@H](C)CC)=O)O)CC(C(N)=O)CC5=CN=CN5)=O)C)=O)CC6=CNC7=CC=CC=C7)=O)CC(O)=O)O)CCC(N)=O)=O=C1.[x]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA